- To understand the potential of perioperative treatments in non-small cell lung cancer (NSCLC)
- To identify patients who should receive perioperative treatment for NSCLC
- To choose the most appropriate perioperative treatment for NSCLC
- To know the modalities of delivery for perioperative treatments in NSCLC
After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.
|Title||Duration||Content||CME Points||CME Test|
|Perioperative Treatment of Non-Small Cell Lung Cancer||25 min.||43 slides||-||-|
In this E-Learning module, the author reviews data on perioperative treatment for non-small cell lung cancer (NSCLC) and puts them into practice perspective.
In particular, she elaborates on perioperative chemotherapy, preoperative chemoradiation, perioperative targeted treatments, perioperative immunotherapy, and postoperative mediastinal radiotherapy.
The module rationally presents data from historical clinical trials, meta-analyses and recently performed clinical investigations in terms of practice in this particular field.Each of the perioperative treatment modalities is illustrated with findings from clinical studies and/or meta-analyses.
The author smoothly navigates through different treatment options, including combinations, providing the strengths and weaknesses of available evidence and challenging the practice patterns against data from, sometimes old, clinical studies performed in that setting.
It is also a very useful review of currently available data on attempts to test modern targeted therapies and checkpoint inhibitors - which showed activity and safety in advanced NSCLC setting - for their application in the treatment of earlier stages of the disease. However, the author clearly concludes that there is no role yet for these agents in perioperative treatment of NSCLC.
The topic of perioperative treatment of NSCLC is an excellent example of the importance of multidisciplinarity for the best outcome in cancer patients. Therefore, this module is intended for different oncology professionals involved in the care of these patients (medical oncologists, radiotherapists, pulmonologists, etc.).
The author summarizes the current evidence very well and indicates the clinical practice pathways in this setting.
This E-Learning module was published in 2017 and expired in 2020.
The author has reported to have been a member of the Speakers’ bureau for BMS, Boehringer Ingelheim, AstraZeneca, Roche, Lilly, MSD and Pierre Fabre; to have received support for meetings from Novartis, Boehringer Ingelheim, AstraZeneca, BMS, Lilly and Pierre Fabre Oncology; to be currently conducting research sponsored by BMS, Merck Serono, Boehringer Ingelheim, Genentech and Lilly.